Status:

COMPLETED

Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' C

Lead Sponsor:

Egetis Therapeutics

Conditions:

Chemotherapy

Colon Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The present feasibility study is designed to find out whether pre-treatment with the compound mangafodipir lowers the frequency and severity of side effects during adjuvant chemotherapy according to t...

Detailed Description

Mangafodipir, manganese (Mn) dipyridoxyl diphosphate, is a catalytic antioxidant and iron chelator recently (2006) suggested for cancer treatment in an Editorial in Journal of the National Cancer Inst...

Eligibility Criteria

Inclusion

  • Histologically proven colon cancer stage Dukes' C.
  • Patient over 18 years.
  • WHO performance status \<1.
  • Adequate haematological function (Hb ≥ 100 g/L, ANC ≥ 2.0 x 109/L, platelets ≥ 150 x 109/L)
  • Adequate renal and hepatic functions: serum creatinine and total bilirubin ≤ 1.25 times upper normal limits (ASAT and ALAT ≤ 3 times upper normal limits)
  • Clinical evaluation, haematology and biochemistry performed within 1 week prior to the start of chemotherapy
  • Use of adequate contraception (males with reproductive potential)
  • Written informed consent given

Exclusion

  • Other tumour types than colon adenocarcinomas
  • Current severe neutropenia, leucopenia or thrombocytopenia
  • Severely reduced liver or renal function
  • Unresolved bowel obstruction or sub-obstruction, uncontrolled Crohn's disease or ulcerative colitis
  • Current chronic diarrhoea
  • Contraindication for corticosteroid administration
  • History of prior serious allergic or pseudo-allergic reaction
  • Any other serious illness or medical condition
  • Symptomatic peripheral neuropathy ≥ grade 2
  • Received mangafodipir ≤ 5 weeks before planned start of chemotherapy
  • Received any of the FOLFOX drugs ≤ 5 weeks before planned start of chemotherapy
  • Any plans of administered other anti-cancer therapy (including radiotherapy) concurrent with this study
  • Fertile females
  • Males with reproductive potential not implementing adequate contraception measures
  • Phaeochromocytoma

Key Trial Info

Start Date :

June 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2010

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT00671996

Start Date

June 1 2008

End Date

April 1 2010

Last Update

May 4 2010

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Onkologkliniken, Länssjukhuset Ryhov

Jönköping, Sweden, SE-551 85